Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery
The Union Minister noted that heat stress contributes to a rise in both communicable diseases such as dengue and non-communicable conditions like cardiovascular disorder
The new facility is expected to significantly improve access to high-quality medical services for patients across Gujarat and neighbouring regions
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
Subscribe To Our Newsletter & Stay Updated